Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger

Alumis (ALMS) and ACELYRIN (SLRN) reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, “Alumis and ACELYRIN together will advance exciting breakthroughs for patients and drive long-term value for stockholders through the creation of a leading clinical stage biopharma company in immune-mediated diseases. The combined company will have a significantly strengthened financial position to support a highly differentiated and diverse pipeline with multiple catalysts. With our management team’s successful track-record of developing innovative therapies and an extended runway afforded by combining with ACELYRIN, the transaction will allow us to unlock the value of the combined portfolio for current and future investors and address what we believe is a current dislocation with our valuation. We look forward to completing the combination next quarter and delivering the meaningful benefits of the merger for both companies’ stakeholders.”